The ABPI and DH have agreed to amend the 2014 Pharmaceutical Price Regulation Scheme (PPRS) to clarify the way in which spending under the Cancer Drugs Fund is treated by the Scheme.
Under the new agreement, the Department and the ABPI have sought to protect the interests of all NHS patients, including patients who benefit from the Cancer Drugs Fund, while recognising the need to clarify Cancer Drugs Fund spending within the PPRS.
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
ABPI Press OfficeTelephone: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811Email: email@example.com